The Filing Desk

AbCellera Biologics vs Autolus Therapeutics

AbCellera Biologics ABCL · Autolus Therapeutics AUTL · Biotechnology

Autolus Therapeutics reported revenue of $75 million in fiscal 2025, about the same as AbCellera Biologics' $75 million in fiscal 2025. AbCellera Biologics' revenue grew 160.6% in its latest year, and Autolus Therapeutics' grew 644.9%. AbCellera Biologics had an operating margin of -289.0%, against -358.9% at Autolus Therapeutics. Free cash flow was −$174 million at AbCellera Biologics and −$303 million at Autolus Therapeutics.

Side by side

AbCellera BiologicsAutolus Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$75M$75M
Revenue growth160.6%644.9%
Revenue growth a year, last 5 years−20.3%—
Gross margin—−27.8%
Operating margin−289.0%−358.9%
Net margin−194.9%−381.4%
Free cash flow−$174M−$303M
Free cash flow margin−231.7%−401.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.5%4.3%
Last close$10.47$0.98
P/E at the last close——
Insider trades, last 12 monthsbought $2.7 million, sold $0sold $15,708
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbCellera BiologicsAutolus Therapeutics
Operating margin
Percent of revenue
AbCellera BiologicsAutolus Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbCellera BiologicsAutolus Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbCellera Biologics and Autolus Therapeutics pages.